Literature DB >> 20169212

[Evaluating HIV pre-test counseling in people attending a national hospital in Lima, Peru].

Otto E Mora-Salazar1, Jorge D Palomino-Vargas, Cecilia M Velásquez-Ruiz, Enrique M Gómez-Pomar, Rosa M Castillo-Schilder, Leslie Soto-Arquiñigo, Frine Samalvides-Cuba.   

Abstract

OBJECTIVE: Evaluating the knowledge acquired by the pre-test counselling programme in a national hospital in Lima Peru.
METHOD: A cross-sectional descriptive observational study was carried out on 499 patients attending the National STI/HIV Prevention and Control Sanitary Strategy service after they had been counselled. The patients were intentionally selected by probabilistic means. A questionnaire having direct questions was applied; it had been previously validated by experts. > or = 75 % of correct answers was defined as being a variable of correct knowledge and <75 % of correct answers as incorrect knowledge.
RESULTS: 64.1 % (n=320) of the patients were female. The age group having a better level of knowledge after counselling was the 22-28 year old group, 40.3 % (n=201) (p<0.05). People having a partner diagnosed as having HIV/AIDS answered more questions correctly (12.3 on average). Men showed higher correct knowledge (63.6 %) related to women (36.4 %) (p<0.05). Only 4.4 % (n=22) of the patients had a correct level of knowledge.
CONCLUSION: The pre-test counselling programme did not improve knowledge regarding HIV/AIDS. It is thus suggested that the approach and method should be changed so that patients become well-informed, thereby reducing STI and HIV/AIDS-related morbidity and mortality.

Entities:  

Mesh:

Year:  2009        PMID: 20169212     DOI: 10.1590/s0124-00642009000400007

Source DB:  PubMed          Journal:  Rev Salud Publica (Bogota)        ISSN: 0124-0064


  1 in total

1.  Knowledge about HIV prevention and transmission among recently diagnosed tuberculosis patients: a cross sectional study.

Authors:  Cesar Ugarte-Gil; Mario Ponce; Carlos Zamudio; Luz Canaza; Frine Samalvides; Carlos Seas
Journal:  BMC Public Health       Date:  2013-12-28       Impact factor: 3.295

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.